Skip to content
value.today

Audentes Therapeutics, Inc.

Total raised
$108 M
2 rounds on record
Latest round
$65 M
Oct 2015
First round on record
Nov 2014
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Audentes Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2015$65 MNo. 2$50 to $250 million

Audentes Therapeutics, Inc.: Raise no. 2, Oct 2015

Investors in this round

27 investors had bought by the notice of Oct 22, 2015: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Audentes Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$65 M of $65 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew Patterson · Executive Officer, Director
  • Jonathan Leff · Director
  • Jonathan Silverstein · Director
  • Kush Parmar · Director
  • Louis Lange · Director
  • Steve Squinto · Director
  • Thomas Schuetz · Director
  • Thomas Woiwode · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthew Patterson, President and CEO. Newest notice filed Oct 22, 2015. Read the notice at the SEC.

equitySEC
Nov 2014$43 MNo. 1$10 to $50 million

Audentes Therapeutics, Inc.: Raise no. 1, Nov 2014

Investors in this round

11 investors had bought by the notice of Dec 24, 2014: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Audentes Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$43 M of $43 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Matthew Patterson · Executive Officer, Director
  • Jonathan Leff · Director
  • Jonathan SIlverstein · Director
  • Kush Parmar · Director
  • Thomas Schuetz · Director
  • Thomas Woiwode · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthew Patterson, President and CEO. Newest notice filed Dec 24, 2014. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Audentes Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2015).

    SEC Form D · Oct 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2015

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

14 named in official filings. Open an investor to see everything it has backed.

Investors in Audentes Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
5AM Co-Investors III, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3
5AM Partners III, LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3
5am Ventures III, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Deerfield Mgmt III, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Deerfield Private Design Fund III, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Louis G. LangePersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2016)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner, director (Form 3, 2016)SEC Form 3
OrbiMed Capital GP IV LLCFund or asset managernot statednot statedHeld Series Seed, A, B and C preferred stock, 10% owner, director (Form 3, 2016)SEC Form 3
Versant Side Fund IV, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Versant Venture Capital IV, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3
Versant Ventures IV, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2016)SEC Form 3

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Audentes Therapeutics, Inc.
NameRoleNamed in
Matthew PattersonExecutive officerOct 2015
Jonathan LeffDirectorOct 2015
Jonathan SilversteinDirectorOct 2015
Kush ParmarDirectorOct 2015
Louis LangeDirectorOct 2015
Matthew PattersonDirectorOct 2015
Steve SquintoDirectorOct 2015
Thomas SchuetzDirectorOct 2015
Thomas WoiwodeDirectorOct 2015
Jonathan SIlversteinDirectorDec 2014